Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
89bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ETNB
Nasdaq
8731
https://www.89bio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 89bio Inc
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
- May 2nd, 2024 8:05 pm
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
- Apr 17th, 2024 8:05 pm
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 5th, 2024 8:05 pm
89bio Inc CEO Rohan Palekar Sells 52,718 Shares
- Apr 3rd, 2024 11:01 pm
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
- Mar 27th, 2024 12:00 pm
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
- Mar 18th, 2024 11:00 am
13 Best Biotech Stocks To Buy Under $20
- Mar 13th, 2024 11:07 am
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
- Mar 12th, 2024 12:00 pm
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Mar 8th, 2024 9:05 pm
89bio to Participate in the Leerink Partners Global Biopharma Conference
- Mar 5th, 2024 9:05 pm
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
- Mar 5th, 2024 7:12 pm
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
- Mar 5th, 2024 2:55 pm
89BIO (ETNB) Just Overtook the 200-Day Moving Average
- Mar 5th, 2024 2:30 pm
Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
- Mar 4th, 2024 9:04 pm
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
- Mar 4th, 2024 5:30 pm
89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...
- Mar 2nd, 2024 9:31 am
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Feb 29th, 2024 9:05 pm
11 Best Small-Cap Growth Stocks to Invest In
- Feb 22nd, 2024 8:55 am
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 9:05 pm
89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average
- Jan 18th, 2024 2:35 pm
Scroll